BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30520208)

  • 1. Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomized controlled trial.
    Wittert G; Atlantis E; Allan C; Bracken K; Conway A; Daniel M; Gebski V; Grossmann M; Hague W; Handelsman DJ; Inder W; Jenkins A; Keech A; McLachlan R; Robledo K; Stuckey B; Yeap BB
    Diabetes Obes Metab; 2019 Apr; 21(4):772-780. PubMed ID: 30520208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.
    Wittert G; Bracken K; Robledo KP; Grossmann M; Yeap BB; Handelsman DJ; Stuckey B; Conway A; Inder W; McLachlan R; Allan C; Jesudason D; Fui MNT; Hague W; Jenkins A; Daniel M; Gebski V; Keech A
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):32-45. PubMed ID: 33338415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone and type 2 diabetes prevention: translational lessons from the T4DM study.
    Wittert GA; Grossmann M; Yeap BB; Handelsman DJ
    J Endocrinol; 2023 Sep; 258(3):. PubMed ID: 37227171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.
    Koyasu M; Ishii H; Watarai M; Takemoto K; Inden Y; Takeshita K; Amano T; Yoshikawa D; Matsubara T; Murohara T
    Clin Ther; 2010 Aug; 32(9):1610-7. PubMed ID: 20974318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial.
    Gianatti EJ; Dupuis P; Hoermann R; Strauss BJ; Wentworth JM; Zajac JD; Grossmann M
    Diabetes Care; 2014 Aug; 37(8):2098-107. PubMed ID: 24804695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study.
    Bianchi C; Miccoli R; Trombetta M; Giorgino F; Frontoni S; Faloia E; Marchesini G; Dolci MA; Cavalot F; Cavallo G; Leonetti F; Bonadonna RC; Del Prato S;
    J Clin Endocrinol Metab; 2013 May; 98(5):2100-5. PubMed ID: 23539736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): A double-blind, randomized, placebo-controlled clinical trial.
    Moreira-Lucas TS; Duncan AM; Rabasa-Lhoret R; Vieth R; Gibbs AL; Badawi A; Wolever TM
    Diabetes Obes Metab; 2017 Jan; 19(1):133-141. PubMed ID: 27717236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediation analysis of the testosterone treatment effect to prevent type 2 diabetes in the Testosterone for Prevention of Type 2 Diabetes Mellitus trial.
    Robledo KP; Marschner IC; Handelsman DJ; Bracken K; Stuckey BGA; Yeap BB; Inder W; Grossmann M; Jesudason D; Allan CA; Wittert G
    Eur J Endocrinol; 2023 Jul; 188(7):613-620. PubMed ID: 37406250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In men who are overweight or obese, adding testosterone therapy reduced glucose intolerance/T2DM.
    Griffin TP; Dinneen SF
    Ann Intern Med; 2021 May; 174(5):JC54. PubMed ID: 33939479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study.
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P;
    J Sex Med; 2014 Mar; 11(3):840-56. PubMed ID: 24308723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
    Hemmingsen B; Gimenez-Perez G; Mauricio D; Roqué I Figuls M; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003054. PubMed ID: 29205264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial metabolic effects of chronic glipizide in obese African Americans with impaired glucose tolerance: implications for primary prevention of type 2 diabetes.
    Osei K; Rhinesmith S; Gaillard T; Schuster D
    Metabolism; 2004 Apr; 53(4):414-22. PubMed ID: 15045685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence and the risk factors of testosterone deficiency in newly diagnosed and previously known type 2 diabetic men.
    Ho CH; Jaw FS; Wu CC; Chen KC; Wang CY; Hsieh JT; Yu HJ; Liu SP
    J Sex Med; 2015 Feb; 12(2):389-97. PubMed ID: 25441980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of impaired glucose tolerance prevalence with hemoglobin A₁c and oral glucose tolerance test in 252 Turkish women with polycystic ovary syndrome: a prospective, controlled study.
    Celik C; Abali R; Bastu E; Tasdemir N; Tasdemir UG; Gul A
    Hum Reprod; 2013 Apr; 28(4):1062-8. PubMed ID: 23335611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
    Moelands SV; Lucassen PL; Akkermans RP; De Grauw WJ; Van de Laar FA
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD005061. PubMed ID: 30592787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF; Frandsen CS; Hansen TS; Almdal T; Urhammer S; Pedersen-Bjergaard U; Jensen T; Jensen AK; Holst JJ; Tarnow L; Knop FK; Madsbad S; Andersen HU
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):221-232. PubMed ID: 26656289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
    Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
    Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D Supplementation in Overweight/obese Asian Indian Women with Prediabetes Reduces Glycemic Measures and Truncal Subcutaneous Fat: A 78 Weeks Randomized Placebo-Controlled Trial (PREVENT-WIN Trial).
    Bhatt SP; Misra A; Pandey RM; Upadhyay AD; Gulati S; Singh N
    Sci Rep; 2020 Jan; 10(1):220. PubMed ID: 31937856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.